Treatment of patients with HBV-related decompensated cirrhosis and liver transplanted patients

Clinics in Liver Disease

Volumn 17, Issue 3, 2013, Pages 451-473

  Roche, Bruno ^a,b,c   Samuel, Didier ^a,b,c  

^a HÔPITAL PAUL BROUSSE   (France)

^b INSERM   (France)

^c UNIVERSITÉ PARIS SACLAY   (France)

Author keywords

Antiviral therapy; Cirrhosis; Entecavir; Hepatitis B; Hepatitis B immunoglobulin; Liver transplantation; Tenofovir

Indexed keywords

ADEFOVIR; BILIRUBIN; EMTRICITABINE; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; ENTECAVIR; HEPATITIS B ANTIBODY; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B VACCINE; HEPATITIS B(E) ANTIGEN; LAMIVUDINE; TELBIVUDINE; TENOFOVIR; VIRUS DNA;

ANTIVIRAL ACTIVITY; ANTIVIRAL THERAPY; DECOMPENSATED LIVER CIRRHOSIS; DRUG EFFICACY; DRUG SAFETY; END STAGE LIVER DISEASE; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; LIVER FUNCTION; LIVER TRANSPLANTATION; METABOLIC BONE DISEASE; MIXED INFECTION; MONOTHERAPY; NEPHROTOXICITY; NONHUMAN; REVIEW; SURVIVAL RATE; VIRUS LOAD; VIRUS REPLICATION;

EID: 84881029664     PISSN: 10893261     EISSN: 15578224     Source Type: Journal    
DOI: 10.1016/j.cld.2013.05.003     Document Type: Review

References (105)

1. Fattovich G., Bortolotti F., Donato F. Natural history of chronic hepatitis B: special emphasis on disease progression and prognostic factors. JHepatol 2008, 48(2):335-352.
2. Yao F.Y., Terrault N.A., Freise C., et al. Lamivudine treatment is beneficial in patients with severely decompensated cirrhosis and actively replicating hepatitis B infection awaiting liver transplantation: a comparative study using a matched, untreated cohort. Hepatology 2001, 34(2):411-416.
3. Perrillo R.P., Wright T., Rakela J., et al. Amulticenter United States-Canadian trial to assess lamivudine monotherapy before and after liver transplantation for chronic hepatitis B. Hepatology 2001, 33(2):424-432.
4. Schiff E., Lai C.L., Hadziyannis S., et al. Adefovir dipivoxil for wait-listed and post-liver transplantation patients with lamivudine-resistant hepatitis B: final long-term results. Liver Transpl 2007, 13(3):349-360.
5. Liaw Y.F., Raptopoulou-Gigi M., Cheinquer H., et al. Efficacy and safety of entecavir versus adefovir in chronic hepatitis B patients with hepatic decompensation: a randomized, open-label study. Hepatology 2011, 54(1):91-100.
6. Liaw Y.F., Sheen I.S., Lee C.M., et al. Tenofovir disoproxil fumarate (TDF), emtricitabine/TDF, and entecavir in patients with decompensated chronic hepatitis B liver disease. Hepatology 2011, 53(1):62-72.
7. Shim J.H., Lee H.C., Kim K.M., et al. Efficacy of entecavir in treatment-naive patients with hepatitis B virus-related decompensated cirrhosis. JHepatol 2010, 52(2):176-182.
8. Fontana R.J., Hann H.W., Perrillo R.P., et al. Determinants of early mortality in patients with decompensated chronic hepatitis B treated with antiviral therapy. Gastroenterology 2002, 123(3):719-727.
9. Villeneuve J.P., Condreay L.D., Willems B., et al. Lamivudine treatment for decompensated cirrhosis resulting from chronic hepatitis B. Hepatology 2000, 31(1):207-210.
10. Kim W.R., Terrault N.A., Pedersen R.A., et al. Trends in waiting list registration for liver transplantation for viral hepatitis in the United States. Gastroenterology 2009, 137(5):1680-1686.
11. European Association For The Study Of The Liver EASL clinical practice guidelines: management of chronic hepatitis B. JHepatol 2009, 50(2):227-242.
12. Lok A.S., McMahon B.J. Chronic hepatitis B: update 2009. Hepatology 2009, 50(3):661-662.
13. de Jongh F.E., Janssen H.L., de Man R.A., et al. Survival and prognostic indicators in hepatitis B surface antigen-positive cirrhosis of the liver. Gastroenterology 1992, 103(5):1630-1635.
14. Realdi G., Fattovich G., Hadziyannis S., et al. Survival and prognostic factors in 366 patients with compensated cirrhosis type B: a multicenter study. The Investigators of the European Concerted Action on Viral Hepatitis (EUROHEP). JHepatol 1994, 21(4):656-666.
15. Fattovich G., Stroffolini T., Zagni I., et al. Hepatocellular carcinoma in cirrhosis: incidence and risk factors. Gastroenterology 2004, 127(5 Suppl 1):S35-S50.
16. Fontana R.J., Keeffe E.B., Carey W., et al. Effect of lamivudine treatment on survival of 309 North American patients awaiting liver transplantation for chronic hepatitis B. Liver Transpl 2002, 8(5):433-439.
17. Hann H.W., Fontana R.J., Wright T., et al. AUnited States compassionate use study of lamivudine treatment in nontransplantation candidates with decompensated hepatitis B virus-related cirrhosis. Liver Transpl 2003, 9(1):49-56.
18. Singal A.K., Fontana R.J. Meta-analysis: oral anti-viral agents in adults with decompensated hepatitis B virus cirrhosis. Aliment Pharmacol Ther 2012, 35(6):674-689.
19. Chang T.T., Gish R.G., de Man R., et al. Acomparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. NEngl J Med 2006, 354(10):1001-1010.
20. Lai C.L., Shouval D., Lok A.S., et al. Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B. NEngl J Med 2006, 354(10):1011-1020.
21. Tenney D.J., Rose R.E., Baldick C.J., et al. Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-naive patients is rare through 5 years of therapy. Hepatology 2009, 49(5):1503-1514.
22. Sherman M., Yurdaydin C., Sollano J., et al. Entecavir for treatment of lamivudine-refractory, HBeAg-positive chronic hepatitis B. Gastroenterology 2006, 130(7):2039-2049.
23. Lange C.M., Bojunga J., Hofmann W.P., et al. Severe lactic acidosis during treatment of chronic hepatitis B with entecavir in patients with impaired liver function. Hepatology 2009, 50(6):2001-2006.
24. van Bommel F., Zollner B., Sarrazin C., et al. Tenofovir for patients with lamivudine-resistant hepatitis B virus (HBV) infection and high HBV DNA level during adefovir therapy. Hepatology 2006, 44(2):318-325.
25. Marcellin P., Heathcote E.J., Buti M., et al. Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B. NEngl J Med 2008, 359(23):2442-2455.
26. European Liver Transplant Registry. Available at: Accessed June 17, 2013. http://www.eltr.org.
27. Burra P., Germani G., Adam R., et al. Liver transplantation for HBV-related cirrhosis in Europe: a ELTR study on evolution and outcomes. JHepatol 2013, 58(2):287-296.
28. Wong S.N., Chu C.J., Wai C.T., et al. Low risk of hepatitis B virus recurrence after withdrawal of long-term hepatitis B immunoglobulin in patients receiving maintenance nucleos(t)ide analogue therapy. Liver Transpl 2007, 13(3):374-381.
29. Todo S., Demetris A.J., Van Thiel D., et al. Orthotopic liver transplantation for patients with hepatitis B virus-related liver disease. Hepatology 1991, 13(4):619-626.
30. O'Grady J.G., Smith H.M., Davies S.E., et al. Hepatitis B virus reinfection after orthotopic liver transplantation. Serological and clinical implications. JHepatol 1992, 14(1):104-111.
31. Kim W.R., Poterucha J.J., Kremers W.K., et al. Outcome of liver transplantation for hepatitis B in the United States. Liver Transpl 2004, 10(8):968-974.
32. Degertekin B., Han S.H., Keeffe E.B., et al. Impact of virologic breakthrough and HBIG regimen on hepatitis B recurrence after liver transplantation. Am J Transplant 2010, 10(8):1823-1833.
33. Steinmuller T., Seehofer D., Rayes N., et al. Increasing applicability of liver transplantation for patients with hepatitis B-related liver disease. Hepatology 2002, 35(6):1528-1535.
34. Roche B., Feray C., Gigou M., et al. HBV DNA persistence 10 years after liver transplantation despite successful anti-HBS passive immunoprophylaxis. Hepatology 2003, 38(1):86-95.
35. Hussain M., Soldevila-Pico C., Emre S., et al. Presence of intrahepatic (total and ccc) HBV DNA is not predictive of HBV recurrence after liver transplantation. Liver Transpl 2007, 13(8):1137-1144.
36. Freshwater D.A., Dudley T., Cane P., et al. Viral persistence after liver transplantation for hepatitis B virus: a cross-sectional study. Transplantation 2008, 85(8):1105-1111.
37. Yasunaka T., Takaki A., Yagi T., et al. Serum hepatitis B virus DNA before liver transplantation correlates with HBV reinfection rate even under successful low-dose hepatitis B immunoglobulin prophylaxis. Hepatol Int 2011, 5(4):918-926.
38. Coffin C.S., Mulrooney-Cousins P.M., van Marle G., et al. Hepatitis B virus quasispecies in hepatic and extrahepatic viral reservoirs in liver transplant recipients on prophylactic therapy. Liver Transpl 2011, 17(8):955-962.
39. Lo C.M., Cheung S.T., Lai C.L., et al. Liver transplantation in Asian patients with chronic hepatitis B using lamivudine prophylaxis. Ann Surg 2001, 233(2):276-281.
40. Fung J., Cheung C., Chan S.C., et al. Entecavir monotherapy is effective in suppressing hepatitis B virus after liver transplantation. Gastroenterology 2011, 141(4):1212-1219.
41. Brunetto M.R. Anew role for an old marker, HBsAg. JHepatol 2010, 52(4):475-477.
42. Nguyen T., Thompson A.J., Bowden S., et al. Hepatitis B surface antigen levels during the natural history of chronic hepatitis B: a perspective on Asia. JHepatol 2010, 52(4):508-513.
43. Lenci I., Tisone G., Di Paolo D., et al. Safety of complete and sustained prophylaxis withdrawal in patients liver-transplanted for HBV-related cirrhosis at low risk of HBV recurrence. JHepatol 2011, 55(3):587-593.
44. Ghany M.G., Ayola B., Villamil F.G., et al. Hepatitis B virus S mutants in liver transplant recipients who were reinfected despite hepatitis B immune globulin prophylaxis. Hepatology 1998, 27(1):213-222.
45. Terrault N.A., Zhou S., McCory R.W., et al. Incidence and clinical consequences of surface and polymerase gene mutations in liver transplant recipients on hepatitis B immunoglobulin. Hepatology 1998, 28(2):555-561.
46. Brind A., Jiang J., Samuel D., et al. Evidence for selection of hepatitis B mutants after liver transplantation through peripheral blood mononuclear cell infection. JHepatol 1997, 26(2):228-235.
47. Bock C.T., Tillmann H.L., Torresi J., et al. Selection of hepatitis B virus polymerase mutants with enhanced replication by lamivudine treatment after liver transplantation. Gastroenterology 2002, 122(2):264-273.
48. Marzano A., Gaia S., Ghisetti V., et al. Viral load at the time of liver transplantation and risk of hepatitis B virus recurrence. Liver Transpl 2005, 11(4):402-409.
49. Zheng S., Chen Y., Liang T., et al. Prevention of hepatitis B recurrence after liver transplantation using lamivudine or lamivudine combined with hepatitis B Immunoglobulin prophylaxis. Liver Transpl 2006, 12(2):253-258.
50. Samuel D., Muller R., Alexander G., et al. Liver transplantation in European patients with the hepatitis B surface antigen. NEngl J Med 1993, 329(25):1842-1847.
51. Neff G.W., O'Brien C.B., Nery J., et al. Outcomes in liver transplant recipients with hepatitis B virus: resistance and recurrence patterns from a large transplant center over the last decade. Liver Transpl 2004, 10(11):1372-1378.
52. Mutimer D., Pillay D., Dragon E., et al. High pre-treatment serum hepatitis B virus titre predicts failure of lamivudine prophylaxis and graft re-infection after liver transplantation. JHepatol 1999, 30(4):715-721.
53. Xie S.B., Zhu J.Y., Ying Z., et al. Prevention and risk factors of the HBV recurrence after orthotopic liver transplantation: 160 cases follow-up study. Transplantation 2010, 90(7):786-790.
54. Chun J., Kim W., Kim B.G., et al. High viremia, prolonged lamivudine therapy and recurrent hepatocellular carcinoma predict posttransplant hepatitis B recurrence. Am J Transplant 2010, 10(7):1649-1659.
55. Faria L.C., Gigou M., Roque-Afonso A.M., et al. Hepatocellular carcinoma is associated with an increased risk of hepatitis B virus recurrence after liver transplantation. Gastroenterology 2008, 134(7):1890-1899. [quiz: 2155].
56. Yi N.J., Suh K.S., Cho J.Y., et al. Recurrence of hepatitis B is associated with cumulative corticosteroid dose and chemotherapy against hepatocellular carcinoma recurrence after liver transplantation. Liver Transpl 2007, 13(3):451-458.
57. Saab S., Yeganeh M., Nguyen K., et al. Recurrence of hepatocellular carcinoma and hepatitis B reinfection in hepatitis B surface antigen-positive patients after liver transplantation. Liver Transpl 2009, 15(11):1525-1534.
58. Terrault N.A., Zhou S., Combs C., et al. Prophylaxis in liver transplant recipients using a fixed dosing schedule of hepatitis B immunoglobulin. Hepatology 1996, 24(6):1327-1333.
59. Muller R., Gubernatis G., Farle M., et al. Liver transplantation in HBs antigen (HBsAg) carriers. Prevention of hepatitis B virus (HBV) recurrence by passive immunization. JHepatol 1991, 13(1):90-96.
60. Hwang S., Ahn C.S., Song G.W., et al. Posttransplantation prophylaxis with primary high-dose hepatitis B immunoglobulin monotherapy and complementary preemptive antiviral add-on. Liver Transpl 2011, 17(4):456-465.
61. Shouval D., Samuel D. Hepatitis B immune globulin to prevent hepatitis B virus graft reinfection following liver transplantation: a concise review. Hepatology 2000, 32(6):1189-1195.
62. Di Paolo D., Tisone G., Piccolo P., et al. Low-dose hepatitis B immunoglobulin given "on demand" in combination with lamivudine: a highly cost-effective approach to prevent recurrent hepatitis B virus infection in the long-term follow-up after liver transplantation. Transplantation 2004, 77(8):1203-1208.
63. Dickson R.C., Terrault N.A., Ishitani M., et al. Protective antibody levels and dose requirements for IV 5% Nabi hepatitis B immune globulin combined with lamivudine in liver transplantation for hepatitis B-induced end stage liver disease. Liver Transpl 2006, 12(1):124-133.
64. Gane E.J., Angus P.W., Strasser S., et al. Lamivudine plus low-dose hepatitis B immunoglobulin to prevent recurrent hepatitis B following liver transplantation. Gastroenterology 2007, 132(3):931-937.
65. Marzano A., Salizzoni M., Debernardi-Venon W., et al. Prevention of hepatitis B virus recurrence after liver transplantation in cirrhotic patients treated with lamivudine and passive immunoprophylaxis. JHepatol 2001, 34(6):903-910.
66. Jiang L., Yan L., Li B., et al. Prophylaxis against hepatitis B recurrence posttransplantation using lamivudine and individualized low-dose hepatitis B immunoglobulin. Am J Transplant 2010, 10(8):1861-1869.
67. Buti M., Mas A., Prieto M., et al. Arandomized study comparing lamivudine monotherapy after a short course of hepatitis B immune globulin (HBIg) and lamivudine with long-term lamivudine plus HBIg in the prevention of hepatitis B virus recurrence after liver transplantation. JHepatol 2003, 38(6):811-817.
68. Han S.H., Ofman J., Holt C., et al. An efficacy and cost-effectiveness analysis of combination hepatitis B immune globulin and lamivudine to prevent recurrent hepatitis B after orthotopic liver transplantation compared with hepatitis B immune globulin monotherapy. Liver Transpl 2000, 6(6):741-748.
69. Markowitz J.S., Martin P., Conrad A.J., et al. Prophylaxis against hepatitis B recurrence following liver transplantation using combination lamivudine and hepatitis B immune globulin. Hepatology 1998, 28(2):585-589.
70. Rosenau J., Bahr M.J., Tillmann H.L., et al. Lamivudine and low-dose hepatitis B immune globulin for prophylaxis of hepatitis B reinfection after liver transplantation possible role of mutations in the YMDD motif prior to transplantation as a risk factor for reinfection. JHepatol 2001, 34(6):895-902.
71. Anselmo D.M., Ghobrial R.M., Jung L.C., et al. New era of liver transplantation for hepatitis B: a 17-year single-center experience. Ann Surg 2002, 235(5):611-619. [discussion: 619-20].
72. Xi Z.F., Xia Q., Zhang J.J., et al. The role of entecavir in preventing hepatitis B recurrence after liver transplantation. JDig Dis 2009, 10(4):321-327.
73. Singham J., Greanya E.D., Lau K., et al. Efficacy of maintenance subcutaneous hepatitis B immune globulin (HBIG) post-transplant for prophylaxis against hepatitis B recurrence. Ann Hepatol 2011, 9(2):166-171.
74. Yahyazadeh A., Beckebaum S., Cicinnati V., et al. Efficacy and safety of subcutaneous human HBV-immunoglobulin (Zutectra) in liver transplantation: an open, prospective, single-arm phase III study. Transpl Int 2011, 24(5):441-450.
75. Hooman N., Rifai K., Hadem J., et al. Antibody to hepatitis B surface antigen trough levels and half-lives do not differ after intravenous and intramuscular hepatitis B immunoglobulin administration after liver transplantation. Liver Transpl 2008, 14(4):435-442.
76. Cholongitas E., Goulis J., Akriviadis E., et al. Hepatitis B immunoglobulin and/or nucleos(t)ide analogues for prophylaxis against hepatitis b virus recurrence after liver transplantation: a systematic review. Liver Transpl 2011, 17(10):1176-1190.
77. Rao W., Wu X., Xiu D. Lamivudine or lamivudine combined with hepatitis B immunoglobulin in prophylaxis of hepatitis B recurrence after liver transplantation: a meta-analysis. Transpl Int 2009, 22(4):387-394.
78. Katz L.H., Paul M., Guy D.G., et al. Prevention of recurrent hepatitis B virus infection after liver transplantation: hepatitis B immunoglobulin, antiviral drugs, or both? Systematic review and meta-analysis. Transpl Infect Dis 2009, 12(4):292-308.
79. Loomba R., Rowley A.K., Wesley R., et al. Hepatitis B immunoglobulin and lamivudine improve hepatitis B-related outcomes after liver transplantation: meta-analysis. Clin Gastroenterol Hepatol 2008, 6(6):696-700.
80. Jimenez-Perez M., Saez-Gomez A.B., Mongil Poce L., et al. Efficacy and safety of entecavir and/or tenofovir for prophylaxis and treatment of hepatitis B recurrence post-liver transplant. Transplant Proc 2010, 42(8):3167-3168.
81. Sanchez-Fueyo A., Rimola A., Grande L., et al. Hepatitis B immunoglobulin discontinuation followed by hepatitis B virus vaccination: a new strategy in the prophylaxis of hepatitis B virus recurrence after liver transplantation. Hepatology 2000, 31(2):496-501.
82. Angelico M., Di Paolo D., Trinito M.O., et al. Failure of a reinforced triple course of hepatitis B vaccination in patients transplanted for HBV-related cirrhosis. Hepatology 2002, 35(1):176-181.
83. Bienzle U., Gunther M., Neuhaus R., et al. Immunization with an adjuvant hepatitis B vaccine after liver transplantation for hepatitis B-related disease. Hepatology 2003, 38(4):811-819.
84. Albeniz Arbizu E., Barcena Marugan R., Oton Nieto E., et al. Prophylaxis of recurrent hepatitis B virus by vaccination after liver transplant: preliminary results. Transplant Proc 2003, 35(5):1848-1849.
85. Lo C.M., Liu C.L., Chan S.C., et al. Failure of hepatitis B vaccination in patients receiving lamivudine prophylaxis after liver transplantation for chronic hepatitis B. JHepatol 2005, 43(2):283-287.
86. Rosenau J., Hooman N., Hadem J., et al. Failure of hepatitis B vaccination with conventional HBsAg vaccine in patients with continuous HBIG prophylaxis after liver transplantation. Liver Transpl 2007, 13(3):367-373.
87. Weber N.K., Forman L.M., Trotter J.F. HBIg discontinuation with maintenance oral anti-viral therapy and HBV vaccination in liver transplant recipients. Dig Dis Sci 2010, 55(2):505-509.
88. Di Paolo D., Lenci I., Cerocchi C., et al. One-year vaccination against hepatitis B virus with a MPL-vaccine in liver transplant patients for HBV-related cirrhosis. Transpl Int 2010, 23(11):1105-1112.
89. Gunther M., Neuhaus R., Bauer T., et al. Immunization with an adjuvant hepatitis B vaccine in liver transplant recipients: antibody decline and booster vaccination with conventional vaccine. Liver Transpl 2006, 12(2):316-319.
90. Dodson S.F., de Vera M.E., Bonham C.A., et al. Lamivudine after hepatitis B immune globulin is effective in preventing hepatitis B recurrence after liver transplantation. Liver Transpl 2000, 6(4):434-439.
91. Naoumov N.V., Lopes A.R., Burra P., et al. Randomized trial of lamivudine versus hepatitis B immunoglobulin for long-term prophylaxis of hepatitis B recurrence after liver transplantation. JHepatol 2001, 34(6):888-894.
92. Buti M., Mas A., Prieto M., et al. Adherence to lamivudine after an early withdrawal of hepatitis B immune globulin plays an important role in the long-term prevention of hepatitis B virus recurrence. Transplantation 2007, 84(5):650-654.
93. Angus P.W., Patterson S.J., Strasser S.I., et al. Arandomized study of adefovir dipivoxil in place of HBIG in combination with lamivudine as post-liver transplantation hepatitis B prophylaxis. Hepatology 2008, 48(5):1460-1466.
94. Saab S., Desai S., Tsaoi D., et al. Posttransplantation hepatitis B prophylaxis with combination oral nucleoside and nucleotide analog therapy. Am J Transplant 2011, 11(3):511-517.
95. Neff G.W., Kemmer N., Kaiser T.E., et al. Combination therapy in liver transplant recipients with hepatitis B virus without hepatitis B immune globulin. Dig Dis Sci 2007, 52(10):2497-2500.
96. Teperman L.W., Poordad F., Bzowej N., et al. Randomized trial of emtricitabine/tenofovir disoproxil fumarate after hepatitis B immunoglobulin withdrawal after liver transplantation. Liver Transpl 2013, 19(6):594-601.
97. Grellier L., Mutimer D., Ahmed M., et al. Lamivudine prophylaxis against reinfection in liver transplantation for hepatitis B cirrhosis. Lancet 1996, 348(9036):1212-1215.
98. Malkan G., Cattral M.S., Humar A., et al. Lamivudine for hepatitis B in liver transplantation: a single-center experience. Transplantation 2000, 69(7):1403-1407.
99. Mutimer D., Dusheiko G., Barrett C., et al. Lamivudine without HBIg for prevention of graft reinfection by hepatitis B: long-term follow-up. Transplantation 2000, 70(5):809-815.
100. Yoshida H., Kato T., Levi D.M., et al. Lamivudine monoprophylaxis for liver transplant recipients with non-replicating hepatitis B virus infection. Clin Transplant 2007, 21(2):166-171.
101. Lo C.M., Liu C.L., Lau G.K., et al. Liver transplantation for chronic hepatitis B with lamivudine-resistant YMDD mutant using add-on adefovir dipivoxil plus lamivudine. Liver Transpl 2005, 11(7):807-813.
102. Fox A.N., Terrault N.A. The option of HBIG-free prophylaxis against recurrent HBV. JHepatol 2012, 56(5):1189-1197.
103. Wadhawan M.G., Gupta S., Vij V., et al. Living related liver transplant (LRLT) in HBV DNA negative cirrhosis without hepatitis B immune globulin (HBIG). Hepatol Int 2011, 5:38. (Abstract).
104. Tan J., Lok A.S. Antiviral therapy for pre- and post-liver transplantation patients with hepatitis B. Liver Transpl 2007, 13(3):323-326.
105. Perrillo R., Hann H.W., Mutimer D., et al. Adefovir dipivoxil added to ongoing lamivudine in chronic hepatitis B with YMDD mutant hepatitis B virus. Gastroenterology 2004, 126(1):81-90.